Optos floated on the LSE in 2006 and was aquired by Nikon Corporation in 2015. The original investment was made by Archangels in 1992.
Optos’ platform technology is the Panoramic200 Scanning Laser Ophthalmoscope device, known as the P200. In a quarter of a second the P200 produces a high resolution image of up to 200 degrees or approximately 82% of the retina in a single capture. The image, branded the optomap Retinal Exam, provides eye care practitioners with clinically useful information that facilitates the early detection of disorders and diseases evidenced in the retina, such as glaucoma, diabetic retinopathy and age-related macular degeneration.
Retinal imaging can also indicate evidence of non-eye or systemic diseases such as diabetes, hypertension and certain cancers. Optos’ technology provides an unequaled combination of ultra-widefield retinal imaging, speed and convenience for both practitioner and patient and can help save sight and save lives.